#ADC #Mabwell #Triple Negative Breast Cancer

Mabwell's Groundbreaking Presentation at ESMO 2026

Mabwell, a prominent biopharmaceutical company known for its innovative approaches in oncology, is gearing up for a significant appearance at the 2026 European Society for Medical Oncology (ESMO) Annual Congress in Madrid. The event will take place from October 23 to October 27, where Mabwell will unveil the latest advancements in its clinical studies regarding the novel antibody-drug conjugate (ADC), known as 9MW2821, specifically targeting Nectin-4 for triple-negative breast cancer (TNBC).

Clinical Focus on 9MW2821

The oral presentation will feature the latest clinical study results which delve into the efficacy of 9MW2821 in patients experiencing locally advanced or metastatic TNBC. This condition, recognized for its aggressive nature and lack of targeted therapies, emphasizes the importance of innovative treatments. Under the title, “Bulumtatug Fuvedotin (BFv, 9MW2821), a Nectin-4-Directed Antibody-Drug Conjugate (ADC), in Patients with Locally Advanced or Metastatic Triple Negative Breast Cancer (la/mTNBC) Previously Treated with Topoisomerase I Inhibitor (Topl)-Based ADCs: Results from a Phase 2 Study.”, the findings promise to shed light on the treatment's potential.

The session, which is scheduled for October 26 at 10:15 AM Berlin time, will be led by Professor ZHANG Jian, the Chief Physician and Doctoral Supervisor at Fudan University Shanghai Cancer Center. His expertise in the field and the relevance of this presentation could mark a pivotal moment in the treatment landscape of TNBC.

The Path Ahead

Mabwell is dedicated to advancing the frontiers of medical science, focusing not only on oncology but also on aging-related diseases. With the corporate mission